<DOC>
	<DOCNO>NCT00562406</DOCNO>
	<brief_summary>The primary objective pilot study compare functional anatomic outcome chronic macular edema secondary branch retinal vein occlusion ( BRVO ) treat argon laser photocoagulation versus intravitreal ranibizumab ( Lucentis® ) injection versus combination .</brief_summary>
	<brief_title>Ranibizumab Branch Retinal Vein Occlusion Associated Macular Edema Study ( RABAMES )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adults age 18 year old chronic ( &gt; 3months , &lt; 18 month ) macular edema secondary branch retinal vein occlusion Patients baseline BSCVA study eye 20/320 equivalent 20/40 , use ETDRS chart measure 4 meter Patients baseline chronic macular edema ( &gt; 3 month ) study eye follow characteristic determine fluorescein angiography : Evidence macular edema extend geometric center foveal avascular zone . Evidence edema secondary BRVO ( relevant ocular disease , e.g . uveitis ) . Patients baseline chronic macular edema ( &gt; 3 month ) study eye follow characteristic determine optical coherence tomography ( OCT 3 ) : Evidence central macular thickness &gt; 225 μm . Ability subject understand character individual consequence clinical trial . Signed date informed consent subject must available start specific trial procedure . For woman childbearing potential , adequate contraception ( negative pregnancy test result , serum urine trial entry , treatment end study ) . Only one eye patient may include trial . Patients baseline Have relevant ocular disease may associate increase intraocular VEGF level ( namely uveitis , neovascular glaucoma , neovascular agerelated macular degeneration , diabetic retinopathy , diabetic maculopathy , ocular ischemic syndrome , others ) Have relevant systemic disease may associate increased systemic VEGF level ( namely malignancy ) Had previous treatment macular edema ( laser , triamcinolone , vitrectomy ) Pregnancy lactation . History hypersensitivity investigational medicinal product drug similar chemical structure excipient present pharmaceutical form investigational medicinal product . Participation clinical trial within last 3 month . Medical psychological condition would permit completion trial signing informed consent . Arterial hypertension refractory medical treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Macular edema secondary branch retinal vein occlusion</keyword>
</DOC>